The Synthetic Androgen Methyltrienolone (R1881) Acts as a Potent Antagonist of the Mineralocorticoid Receptor

@article{Takeda2007TheSA,
  title={The Synthetic Androgen Methyltrienolone (R1881) Acts as a Potent Antagonist of the Mineralocorticoid Receptor},
  author={Armelle-Natsuo Takeda and Grégory Maurice Pinon and Marcelle Bens and J{\'e}r{\^o}me Fagart and Marie-Edith Rafestin-Oblin and Alain Vandewalle},
  journal={Molecular Pharmacology},
  year={2007},
  volume={71},
  pages={473 - 482}
}
Aldosterone binds to the mineralocorticoid receptor (MR) and exerts fine control over Na+ absorption in renal collecting duct cells (CCDs). Many natural and synthetic steroids can also bind to the MR to produce agonist or antagonist effects. Here, we investigate whether androgenic hormones act as MR agonist or antagonist ligands in CCDs. Testosterone (T), dihydrotestosterone (DHT), and methyltrienolone (R1881), a synthetic androgen agonist, all bind to the MR. R1881 displayed the same affinity… 
View on ASPET
molpharm.aspetjournals.org
20 Citations
Background Citations
10

Figures from this paper

20 Citations

Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites

Aldosterone, mineralocorticoid receptor, and heart failure

Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain

This review aims to present and comprehensively discuss molecules that affect AR signaling through direct or indirect interactions with the AR‐TAD or the DBD, and highlights the significant in vitro and in vivo data found for each compound and the apparent limitations and/or potential for further development of these agents as PCa therapies.

Metabolic modulation induced by oestradiol and DHT in immature rat Sertoli cells cultured in vitro.

The results support the existence of a relation between sex hormones action and energy metabolism, providing an important assessment of androgens and oestrogens as metabolic modulators in rat Sertoli cells.

Medicinal Use of Testosterone and Related Steroids Revisited

Although these agents are currently regarded as rather older generation drugs and their use may lead to serious side-effects, they still have medicinal value as androgenic, anabolic, and even anti-androgenic agents.

A High-Content Glucocorticoid Receptor Translocation Assay for Compound Mechanism-of-Action Evaluation

The authors have developed a robust assay system for the glucocorticoid receptor (GR) that was applied to a panel of nuclear receptor ligands and quantified and a correlation with other conventional assays established.

The Endothelial Mineralocorticoid Receptor: Contributions to Sex Differences in Cardiovascular Disease.

Anabolic steroid excess promotes hydroelectrolytic and autonomic imbalance in adult male rats: Is it enough to alter blood pressure?

Novel Hormonal Combination Therapy for Triple Negative Breast Cancer

AR/VDR targeted agonist hormone therapy can inhibit HR2av TNBC through multiple mechanisms in a receptor dependent manner and can be combined with chemotherapy.

Cell models for studying renal physiology

This review provides an overview of the use of immortalized mouse tubules cell lines for in vitro analyses of various tubule cell-specific functions and the regulation of ion transporters and membranous channels.

References

SHOWING 1-10 OF 56 REFERENCES

11β-Hydroxyprogesterone Acts as a Mineralocorticoid Agonist in Stimulating Na+ Absorption in Mammalian Principal Cortical Collecting Duct Cells

It is demonstrated that in the absence of the 21-hydroxyl group, the 11β-hydroxyyl group can produce the contact with the hMR-Asn770 required for the h MR activation leading to stimulated Na + absorption.

Specific Recognition of Androgens by Their Nuclear Receptor

A homology model of the ligand-binding domain (LBD) of the human androgen receptor (hAR) was constructed based on the progesterone receptor LBD crystal structure, which suggests new directions for drug design.

Androgen receptor antagonists (antiandrogens): structure-activity relationships.

There is a need for next-generation antiandrogens, which could display an equal or even higher affinity for AR compared to the natural androgens, and at the same time maintain its pure antiandrogenic activity, and thus providing improved androgen blockade using possibly anti androgens alone.

Differences between aldosterone and its antagonists in binding kinetics and ligand-induced hsp90 release from mineralocorticosteroid receptor

Affinity of corticosteroids for mineralocorticoid and glucocorticoid receptors of the rabbit kidney: effect of steroid substitution.

Antagonism in the human mineralocorticoid receptor

A new mechanism of antagonism is proposed in which the AF2‐AD core region is destabilized by the loss of contacts between the antagonist and the helix H12 region, proposed in the light of the hMR homology model.

Testosterone: a specific competitive antagonist of aldosterone in the toad bladder.

It is concluded that testosterone is a specific competitive antagonist of aldosterone, and [3H]aldosterone nuclear and cytoplasmic binding sites could be mineralocorticoid receptors, mediating the action of a Aldosterone on Na+ transport.

The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms.

The coregulator and corepressor interactions with the mineralocorticoid receptor (MR) indicate that MR ligand binding domain (LBD) interacts strongly with only a few specific coactivator peptides in the presence of the agonist aldosterone and that these interactions are blocked by the antagonist eplerenone.

Folding requirements of the ligand-binding domain of the human mineralocorticoid receptor.

The results support the idea that a short sequence upstream of the LBD is essential for the interaction of hMR with hsp90 and that the C terminus of h MR and hSp90 are both essential for folding of the receptor in a high-affinity hormone-binding state.

RU-26988--a new tool for the study of the mineralocorticoid receptor.

RU-26988 is a recently synthesized glucocorticoid that shows very low affinity for the mineralocortioid receptor and has over twice the ability of unlabeled dexamethasone to compete with [3H]dexameth asone for binding to the renal cytosol glucoc Corticoid receptor.
...